SENISCA
United Kingdom
- Exeter, Devon
- 19/03/2024
- Unknown
- $4,694,134
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).
Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.
At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.
- Industry Biotechnology
- Website https://www.senisca.com/
- LinkedIn https://www.linkedin.com/company/senisca/
Navier AI | $6,500,000 | (Dec 17, 2025)
AIR Platforms | $6,100,000 | (Dec 17, 2025)
Auxira Health | $7,800,000 | (Dec 17, 2025)
Mirelo AI | $41,000,000 | (Dec 17, 2025)
Lucis (YC X25) | $8,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)
Nanit | $50,000,000 | (Dec 17, 2025)
Culture Biosciences | Undisclosed Amount | (Dec 17, 2025)
YSE Beauty | $15,000,000 | (Dec 17, 2025)
Vital Lyfe | $24,000,000 | (Dec 17, 2025)
Dux Security | $9,000,000 | (Dec 17, 2025)